Tag: lymphoblastic
Cellectis: UCART22 has been administered to a first patient for the treatment of acute lymphoblastic leukemia
(Boursier.com) — Cellectis a clinical-stage biotechnology company that uses its pioneering TALEN genome-editing technology to develop innovative therapies for the treatment of serious diseases, today announces that its in-house manufactured…
OSE Immunotherapeutics presents the latest preclinical efficacy data of its IL-7 receptor antagonist OSE-127 in acute lymphoblastic leukemia at the 2022 ASH Annual Meeting – 12/12/2022 at 07:30
Nantes, France – December 12, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the latest preclinical data on the use of its IL-7 receptor antagonist (IL-7R)…